Why is Galderma stock surging today?

Galderma stock experienced a significant surge of 4.6% today following the release of its Q3 trading update and a raised full-year growth outlook for the second consecutive time this year. The third-quarter net sales amounted to $1.63 billion, which exceeded the average analyst estimate by 5%, growing at a rate of 26.0% at constant currency. Notably, every product line surpassed its respective forecasts, with Therapeutic Dermatology leading the charge due to persistent strong demand for Nemulio.

The company's full-year net sales growth guidance was also raised to a range of 22.5%–23.5% at constant currency, a significant increase from the previous range of 19%–21%. This boost was well above the analyst consensus of approximately 21.4%. The strong performance was evident across all three divisions - Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare.

UBS upped its rating to Buy with a price target of CHF 200, while Jefferies maintained its Buy rating and raised its price target to CHF 205. CEO Flemming Ørnskov attributed the guidance increase to the company's confidence in its business, while emphasizing the robust demand for their differentiated, premium portfolio.

Interestingly, despite a generally negative performance of U.S. equities, with the S&P 500 down 1.0%, the Dow Jones off 0.6%, and the Nasdaq declining 1.7%, Galderma's stock managed to outperform the broader market. The Swiss Market Index (SMI) itself experienced a slight decline, making Galderma's outperformance entirely self-generated.

As a result, the stock became the top gainer among SMI constituents, a remarkable feat given the cautious tone of the broader index. Overall, the combination of a broad-based revenue beat, an upgraded annual outlook, and a chorus of bullish analyst reaffirmations led to investors re-rating the stock higher during the session, bringing it closer to its 52-week high of CHF 188.25, but still below it.